Results 21 to 30 of about 3,844,628 (256)
New horizons in hepatitis C antiviral therapy with direct-acting antivirals [PDF]
Hepatology, 2013 Abstract Most direct-acting antivirals (DAAs) that are being developed as therapy against hepatitis C virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter enzyme offers different target sites: the catalytic domain for nucleos(t)ide analogues as well as a number of allosteric sites ...
Alessio, Aghemo, Raffaele, De Francesco
openaire +2 more sources
HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals [PDF]
Journal of Clinical and Translational Hepatology, 2016 Therapy for human immunodeficiency virus (HIV) and chronic hepatitis C has evolved over the past decade, resulting in better control of infection and clinical outcomes; however, drug-drug interactions remain a significant hazard. Joint recommendations from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of ...
Rice, Donald P. +3 more
openaire +2 more sources
Post-crisis imaginaries in the time of direct-acting antiviral hepatitis C treatment
, 2022 Post-crisis imaginaries in the time of direct-acting antiviral hepatitis C ...
Renae Fomiatti (13070133) +5 more
core +1 more source
Insulin resistance and portal heamodynamics changes before and after treatment by new direct antivirals drugs in chronic HCV [PDF]
Afro-Egyptian Journal of Infectious and Endemic Diseases, 2019 Background and study aim: Insulin resistance is typically associated with chronic hepatitis C virus and its improvement after treatment of HCV with new direct antiviral drugs may change portal hemodynamics.
Mahmoud Elsayed +2 more
doaj +1 more source
Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea [PDF]
Clinical and Molecular Hepatology, 2015 Background/AimsThe previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions.
Yuri Cho +5 more
doaj +1 more source
Update on hepatitis C: Direct-acting antivirals
World Journal of Hepatology, 2015 Hepatitis C virus (HCV) was discovered 26 years ago. For decades, interferon-based therapy has been the mainstay of treatment for HCV. Recently, several direct-acting antivirals (DAAs) have been approved for treatment of HCV-infected patients and to help combat the virus.
Leon L, Seifert +2 more
openaire +2 more sources
Mortality associated with the treatment of HCV with direct-acting antivirals [PDF]
Gut, 2017 We read with interest the study by Welzel et al 1 confirming the high efficacy of oral direct-acting antiviral agents (DAAs) for the treatment of chronic HCV infection.2 Results about safety are less clear, since in these patients who have a high risk of hepatic decompensation or death within 12 months, the rate of death was 7.8% during treatment and ...
Anne, Laurain +5 more
openaire +2 more sources
PLoS ONE, 2019 BackgroundData on initiation and utilization of direct-acting antiviral therapies for hepatitis C virus infection in the United States are limited. This study evaluated treatment initiation, time to treatment, and real-world effectiveness of direct ...
Paul Y Kwo +5 more
doaj +1 more source
BMC Infectious Diseases, 2019 Background Almost 1% of Canadians are hepatitis C (HCV)-infected. The liver-specific complications of HCV are established but the extra-hepatic comorbidity, multimorbidity, and its relationship with HCV treatment, is less well known.
Curtis L. Cooper +6 more
doaj +1 more source
Journal of Mind and Medical Sciences, 2019 The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but
Olga H. Orasan +12 more
doaj +1 more source